Ironwood Pharma (IRWD) Reports Q1 Lost Per Share of 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update
May 5, 2015 4:02 PM EDTLINZESS® (linaclotide) U.S. net sales of $95.5 million in first quarter 2015
Total LINZESS prescriptions increased approximately 90% in first quarter 2015 compared to first quarter 2014
Reported positive top-line data from IW-3718 Phase IIa study for refractory GERD
Advanced sGC platform with initiation of first candidate, IW-1973, into Phase I study
Established agreement with Exact Sciences to co-promote Cologuard®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
